We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 9, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ShockWave Medical (SWAV - Free Report) , CheckCap (CHEK - Free Report) and Biosig Technologies (BSGM - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
3 Medical Instruments Stocks with Potential to Outperform
In recent years, the medical instruments industry, part of the wider Medical sector, has seen a transformation in the nature of its business that led to higher research and development activities for developing cutting-edge technologies. The industry's landscape changed further with the onset of the COVID-19 crisis that put robotic and remote services in the limelight.
However, the industry is currently facing several challenges, including deteriorating international trade conditions and global inflationary pressure. These developments have resulted in an extremely tough situation related to raw material and labor costs as well as freight charges. Moreover, the uncertainty surrounding another resurgence of COVID-19 infections amid the emergence of new COVID strains in several parts of the world has raised concerns related to the magnitude of economic revival following the reopening of the economies.
Although the industry faced headwinds, a few medical instruments companies were able to maintain their recovery trend in the first half of 2022. However, staffing shortages and supply chain-related hazards are likely to hurt the industry players in the rest of 2022.
Here we discuss three medical instruments stocks — ShockWave Medical, CheckCap and Biosig Technologies — which are likely to outperform the industry going forward despite macro headwinds and a gloomy world economic outlook. These stocks carry a Zacks Rank #1 (Strong Buy) or 2 (Buy). These stocks also have a Momentum Score of A or B, which indicates that these would be good stocks for momentum investors based on recent price changes and earnings estimate revisions.
ShockWave Medical
The company carries a Zacks Rank #1. ShockWave Medical has a Momentum Score of B. The Zacks Consensus Estimate for earnings has moved 25.4% and 15.2% north for 2022 and 2023, respectively, in the past 60 days.
The increased adoption of coronary IVL in the United States, continued sales force expansion, growing international expansion and higher adoption of Shockwave products are likely to boost the company's performance. The company's strong global growth highlights the significant clinical need for a better calcium treatment and how well the team at ShockWave Medical is addressing the same with IVL.
CheckCap
The company carries a Zacks Rank #1. CheckCap has a Momentum Score of A. The Zacks Consensus Estimate for loss has narrowed 5% and 5.3% for 2022 and 2023, respectively, in the past 60 days.
CheckCap is a clinical-stage company that initiated a pivotal study on C-Scan, during the second quarter 2022, that focuses on device calibration and enhancement of C-Scan algorithms among the average risk U.S. population. A positive study outcome will likely bolster the company's prospects.
Biosig Technologies
The company carries a Zacks Rank of 2. Biosig Technologies has a Momentum Score of A. The Zacks Consensus Estimate for loss has narrowed 3% for 2022 and remained stable for 2023 in the past 60 days.
Biosig Technologies is principally devoted to improving the standard care in electrophysiology with its PURE EP System's enhanced signal acquisition, digital signal processing, and analysis during the ablation of cardiac arrhythmias. The company is carrying out a national rollout strategy to support the availability of its PURE EP System.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
For Immediate Release
Chicago, IL – September 9, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ShockWave Medical (SWAV - Free Report) , CheckCap (CHEK - Free Report) and Biosig Technologies (BSGM - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
3 Medical Instruments Stocks with Potential to Outperform
In recent years, the medical instruments industry, part of the wider Medical sector, has seen a transformation in the nature of its business that led to higher research and development activities for developing cutting-edge technologies. The industry's landscape changed further with the onset of the COVID-19 crisis that put robotic and remote services in the limelight.
However, the industry is currently facing several challenges, including deteriorating international trade conditions and global inflationary pressure. These developments have resulted in an extremely tough situation related to raw material and labor costs as well as freight charges. Moreover, the uncertainty surrounding another resurgence of COVID-19 infections amid the emergence of new COVID strains in several parts of the world has raised concerns related to the magnitude of economic revival following the reopening of the economies.
Although the industry faced headwinds, a few medical instruments companies were able to maintain their recovery trend in the first half of 2022. However, staffing shortages and supply chain-related hazards are likely to hurt the industry players in the rest of 2022.
Here we discuss three medical instruments stocks — ShockWave Medical, CheckCap and Biosig Technologies — which are likely to outperform the industry going forward despite macro headwinds and a gloomy world economic outlook. These stocks carry a Zacks Rank #1 (Strong Buy) or 2 (Buy). These stocks also have a Momentum Score of A or B, which indicates that these would be good stocks for momentum investors based on recent price changes and earnings estimate revisions.
ShockWave Medical
The company carries a Zacks Rank #1. ShockWave Medical has a Momentum Score of B. The Zacks Consensus Estimate for earnings has moved 25.4% and 15.2% north for 2022 and 2023, respectively, in the past 60 days.
The increased adoption of coronary IVL in the United States, continued sales force expansion, growing international expansion and higher adoption of Shockwave products are likely to boost the company's performance. The company's strong global growth highlights the significant clinical need for a better calcium treatment and how well the team at ShockWave Medical is addressing the same with IVL.
CheckCap
The company carries a Zacks Rank #1. CheckCap has a Momentum Score of A. The Zacks Consensus Estimate for loss has narrowed 5% and 5.3% for 2022 and 2023, respectively, in the past 60 days.
CheckCap is a clinical-stage company that initiated a pivotal study on C-Scan, during the second quarter 2022, that focuses on device calibration and enhancement of C-Scan algorithms among the average risk U.S. population. A positive study outcome will likely bolster the company's prospects.
Biosig Technologies
The company carries a Zacks Rank of 2. Biosig Technologies has a Momentum Score of A. The Zacks Consensus Estimate for loss has narrowed 3% for 2022 and remained stable for 2023 in the past 60 days.
Biosig Technologies is principally devoted to improving the standard care in electrophysiology with its PURE EP System's enhanced signal acquisition, digital signal processing, and analysis during the ablation of cardiac arrhythmias. The company is carrying out a national rollout strategy to support the availability of its PURE EP System.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.